EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom



HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom



Atherosclerosis 255: 128-139



This consensus statement addresses the current three main modalities of treatment of homozygous familial hypercholesterolaemia (HoFH): pharmacotherapy, lipoprotein (Lp) apheresis and liver transplantation. HoFH may cause very premature atheromatous arterial disease and death, despite treatment with Lp apheresis combined with statin, ezetimibe and bile acid sequestrants. Two new classes of drug, effective in lowering cholesterol in HoFH, are now licensed in the United Kingdom. Lomitapide is restricted to use in HoFH but, may cause fatty liver and is very expensive. PCSK9 inhibitors are quite effective in receptor defective HoFH, are safe and are less expensive. Lower treatment targets for lipid lowering in HoFH, in line with those for the general FH population, have been proposed to improve cardiovascular outcomes. HEART UK presents a strategy combining Lp apheresis with pharmacological treatment to achieve these targets in the United Kingdom (UK). Improved provision of Lp apheresis by use of existing infrastructure for extracorporeal treatments such as renal dialysis is promoted. The clinical management of adults and children with HoFH including advice on pregnancy and contraception are addressed. A premise of the HEART UK strategy is that the risk of early use of drug treatments beyond their licensed age restriction may be balanced against risks of liver transplantation or ineffective treatment in severely affected patients. This may be of interest beyond the UK.

(PDF emailed within 0-6 h: $19.90)

Accession: 057960604

Download citation: RISBibTeXText

PMID: 27839699

DOI: 10.1016/j.atherosclerosis.2016.10.017



Related references

Recommendations for the management of patients with homozygous familial hypercholesterolaemia: overview of a new European Atherosclerosis Society consensus statement. Atherosclerosis. Supplements 15(2): 26-32, 2015

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. European Heart Journal 35(32): 2146-2157, 2015

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Turk Kardiyoloji Dernegi Arsivi 43 Suppl 1: 1-14, 2016

Homozygous familial hypercholesterolaemia: Spanish adaptation of the position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Consensus document of the Spanish Society of Arteriosclerosis (SEA) and Familial Hypercholesterolaemia Foundation (FHF). Clinica E Investigacion en Arteriosclerosis 27(2): 80-96, 2016

Management of homozygous familial hypercholesterolaemia. Current Opinion in Lipidology 25(3): 237-238, 2014

Management of homozygous familial hypercholesterolaemia in two brothers. Bmj Case Reports 2018: -, 2018

Homozygous familial hypercholesterolaemia: update on management. Paediatrics and International Child Health 36(4): 243-247, 2017

Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet 1(7918): 1208-1211, 1975

New strategies for the management of patients with homozygous familial hypercholesterolaemia. Atherosclerosis. Supplements 15(2): 17-18, 2015

A molecular genetic service for diagnosing individuals with familial hypercholesterolaemia (FH) in the United Kingdom. European Journal of Human Genetics 9(4): 244-252, 2001

Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine. Bmj 304(6838): 1335-1338, 1992

UK consensus position on the management of homozygous familial hypercholesterolaemia and the introduction of new agents. Atherosclerosis 235(2): E252-E253, 2014

Progressive vascular disease in homozygous familial hypercholesterolaemia despite apheresis and heart and liver transplantation. British Journal of Diabetes & Vascular Disease 11(5): 270-272, 2011

Left-heart valve lesions and coronary artery stenoses in homozygous familial hypercholesterolaemia. European Heart Journal 17(ABSTR SUPPL ): 533, 1996

Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet. Diabetes & Endocrinology 4(10): 850-861, 2018